Top

Published in:

01-11-2004 | Letter to the Editor

Rhabdomyosarcoma of the perianal region presenting as acute leukemia

Authors: Rıdvan Ali, Fahir Özkalemkaş, Ülkü Ozan, Tülay Özçelik, Vildan Özkocaman, Gülaydan Filiz, Osman Manavoğlu, Ahmet Tunalı

Published in: Annals of Hematology | Issue 11/2004

Excerpt

Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumor in adolescence and childhood, which becomes manifest by the locally destructive growth of the primary tumor or its metastases. Sometimes no discernible primary lesion can be detected despite widespread dissemination or in some rare cases the disease may be confined to the marrow. Although approximately 60% of soft tissue sarcomas of children are RMS, it constitutes only 2–5% of all soft tissue sarcomas in adults [1‐3]. …

Hicks J, Flaitz C (2002) Rhabdomyosarcoma of the head and neck in children. Oral Oncol 38:450–459CrossRefPubMed

Sandberg AA, Stone JF, Czarnecki L, Cohen JD (2001) Hematologic masquerade of rhabdomyosarcoma. Am J Hematol 68:51–57CrossRefPubMed

Stindl R, Fiegl M, Regele H, Gisslinger H, Breitenseher MJ, Fonatsch C (1998) Alveolar rhabdomyosarcoma in a 68-year-old patient identified by cytogenetic analysis of bone marrow. Cancer Genet Cytogenet 107:43–47CrossRefPubMed

Maywald O, Metzgeroth G, Schoch C, Ludwig WD, Neff W, Hehlmann R, Hastka J (2002) Alveolar rhabdomyosarcoma with bone marrow infiltration mimicking haematological neoplasia. Br J Haematol 119:583CrossRefPubMed

Title: Rhabdomyosarcoma of the perianal region presenting as acute leukemia
Authors: Rıdvan Ali
Fahir Özkalemkaş
Ülkü Ozan
Tülay Özçelik
Vildan Özkocaman
Gülaydan Filiz
Osman Manavoğlu
Ahmet Tunalı
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 11/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-004-0912-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2004

Is the antiplatelet effect of aspirin affected by systemic inflammation?

Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia

Early plasmacytoid dendritic cell leukemia/lymphoma coexpressing myeloid antigenes

Type 1 and type 2 cytokine-producing CD4+ and CD8+ T cells in primary antiphospholipid syndrome

Angioimmunoblastic T-cell lymphoma with renal involvement: a case report of direct bilateral kidney invasion by lymphoma cells

Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials